Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clover BiopharmaceuticalsHKSE:02197 -6.88%28 Gross Margin % is 102.17% as of Dec. 2025, which is 65% above its 10-year median of 61.75. GuruFocus rates HKSE:02197 with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 735 Biotechnology companies, Clover Biopharmaceuticals ranks better than 69.52% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Clover Biopharmaceuticals had a gross margin of 102.17% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Clover Biopharmaceuticals Gross Margin % Related Terms
Clover Biopharmaceuticals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02197 vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, Clover Biopharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clover Biopharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clover Biopharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Clover Biopharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Clover Biopharmaceuticals (HKSE:02197) has a Gross Margin % of 102.17% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Clover Biopharmaceuticals and its competitors. This is 65% above median its historical median of 61.75. Over the past decade, Clover Biopharmaceuticals' Gross Margin % has ranged from 56.16 to 78.20. According to the industry distribution chart, Clover Biopharmaceuticals ranks #224 out of 735 companies in the Biotechnology industry, placing it in the top 30.5%.
Is Clover Biopharmaceuticals' Gross Margin % too high?
Clover Biopharmaceuticals' current Gross Margin % of 102.17% is 65% above median its 10-year median of 61.75. Over the past 10 years, this metric has ranged from a low of 56.16 to a high of 78.20. The Biotechnology industry median Gross Margin % is 60.91. Clover Biopharmaceuticals' value of 102.17% is 67.7% above this industry median. Based on the distribution chart, Clover Biopharmaceuticals ranks #224 out of 735 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Clover Biopharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Clover Biopharmaceuticals' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clover Biopharmaceuticals ranks #224 out of 735 companies for Gross Margin %. This puts Clover Biopharmaceuticals in the upper half of its industry. The industry median Gross Margin % is 60.91. Clover Biopharmaceuticals' value of 102.17% is 67.7% above this benchmark. Historically, Clover Biopharmaceuticals' own Gross Margin % has ranged from 56.16 to 78.20 over the past decade. While the company's 10-year median is 61.75 vs. the industry median of 60.91, Clover Biopharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clover Biopharmaceuticals's current Gross Margin % of 102.17% is 67.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Clover Biopharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clover Biopharmaceuticals's current Gross Margin % is 102.17%, which is 65% above median its own 10-year median of 61.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clover Biopharmaceuticals stock overvalued right now?
Clover Biopharmaceuticals (HKSE:02197) has a current Gross Margin % of 102.17%. The current Gross Margin % is 102.17%, which is 65% above median its 10-year median of 61.75 and 67.7% above the Biotechnology industry median of 60.91. Clover Biopharmaceuticals' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Clover Biopharmaceuticals (HKSE:02197), the current Gross Margin % is 102.17% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to unleashing the power of vaccines to save lives and improve health around the world. The leverage the proprietary Trimer-Tag technology platform to conduct R&D for vaccines that can fulfill unmet needs, with a focus on building a respiratory vaccine franchise to reduce the burden of vaccine-preventable diseases. The Group has only one operating segment, which is the research and development, manufacturing, and commercialisation of vaccines. Geographically, the company earns revenue from Mainland China and Korea.
28GF Score
Get the complete analysis for HKSE:02197
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02197 has been successfully added to your 
